Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Clear near-term catalyst path (on-demand deucrictibant NDA filing targeted for 1H 2026 and pivotal CHAPTER-3 topline expected 3Q 2026), strong cash (~$329M runway into 1H 2027), bullish analyst targets (~60% implied upside) and ~12.6% 3-week rally with price ~15% above 21-day SMA. This makes it an attractive short-term catalyst/momentum trade despite biotech volatility.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Zero Revenue ⢠Cash Cushion ⢠Rich Valuation PHVS has a strong cash-rich, low-debt balance sheet, but as a pre-revenue biotech it is still burning cash heavily with no revenue and a valuation that looks stretched versus book value.
Price Behavior
Key Price Behavior Insights: ⢠Higher lows ⢠Resistance test ⢠Support hold Support Level: $33.0-$33.3 Resistance Level: $35.9-$36.0 PHVS has strengthened over the last month with a steady series of higher lows and about 11% gains, but it is now testing $35.9-$36.0 resistance after a brief pullback, so a clean breakout is needed to confirm more upside.
Sentiment & News
Key News Insights: ⢠FDA acceptance ⢠PDUFA date ⢠HAE momentum Pharvaris reported supportive EAACI 2026 data for deucrictibant and, more importantly, secured FDA acceptance of its NDA for HAE attacks, advancing the program into formal U.S. regulatory review.
AI Summary
PHVS has shifted into a binary, event-driven regulatory story: the NDA is accepted and runway extends to 2028, removing near-term financing risk, but the stock's rich valuation now depends almost entirely on a favorable PDUFA decision for deucrictibant IR and proof of commercial differentiation.
Description
Pharvaris N.V. is a clinicalâstage biopharmaceutical company developing treatments for rare diseases, with a primary program targeting hereditary angioedema (HAE). Its lead smallâmolecule bradykinin B2âreceptor antagonist is in Phase II, and the pipeline includes both an onâdemand oral soft capsule in Phase II and an extendedârelease prophylactic tablet in early clinical testing. The company operates in the Netherlands, Switzerland and the United States and was founded in 2015 with headquarters in Leiden, the Netherlands.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 1 | Apr 8 | PHVS | Pharvaris N.V. | Clear near-term catalyst path (on-demand deucrictibant NDA filing targeted for 1H 2026 and pivotal CHAPTER-3 topline expected 3Q 2026), strong cash (~$329M runway into 1H 2027), bullish analyst targets (~60% implied upside) and ~12.6% 3-week rally with price ~15% above 21-day SMA. This makes it an attractive short-term catalyst/momentum trade despite biotech volatility. | Closed | -6.4% |